FIH Study With CBSO

NCT ID: NCT01960491

Last Updated: 2018-10-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-05-31
• Study Completion Date: 2018-06-30

Brief Summary

The objective of this study is to evaluate the effectiveness and the safety of the intracardiac septal closure device (CBO), as well as the practicability of implantation of this device using the accessories (DS for CBO).

Conditions

Atrial Septal Defect (ASD); Patent Foramen Ovale (PFO)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Device Closure of Atrial Septal Defect

Group Type: EXPERIMENTAL

Device Closure of Atrial Septal Defect

Intervention Type: DEVICE

Device Closure of Atrial Septal Defect by "Carag Bioresorbable Septal Occluder"

Interventions

Device Closure of Atrial Septal Defect

Device Closure of Atrial Septal Defect by "Carag Bioresorbable Septal Occluder"

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age greater than 18 years - no upper limit of age
• Body weight > 40 kg
• Patients with an isolated ASD or PFO determined as suitable for closure via a commercially available device
• In ASD patients, echocardiographic evidence of right ventricular overload, and a stretched diameter of the defect up to 25 mm
• In patients with PFO, echocardiographic evidence of right to left shunt, and intraatrial tunnel length up to 4 mm
• Signed informed consent, respectively ability to give written informed consent after being told of the potential benefits and risks of entering the trial
• For female patients of child bearing capacity: Exclusion of pregnancy before start of the study and willingness to use adequate contraceptive methods to prevent pregnancy during the study

Exclusion Criteria

• ASD/PFO larger than a stretched diameter of 25 mm, or defects unsuitable for percutaneous closure
• Intraatrial tunnel longer than 4 mm
• Multiple or fenestrated ASD, ostium primum or sinus venosus atrial septal defect, coronary sinus defect
• Any significant cardiac valve dysfunction
• Anomalous pulmonary veins
• Defects with inadequate margins, as is consistent with current standards of care, such that the device will not position appropriately so as to avoid interference with other cardiac structure, or that will subject the device to increased risk of embolization post deployment.
• Acquired pathological or congenital deficiencies of the cardiovascular system (any other than ASD; e.g. transposition of vessels, calcification, myocardial infarction, intracardiac thrombi), being clinically significant, respectively interfering in the investigator's opinion with the conduct of study
• Clinically significant dilated cardiomyopathy (paroxysmal or caused by e.g. myocarditis or other reasons)
• Any patient known to have extensive or complex congenital cardiac anomaly which can only be adequately repaired by way of cardiac surgery
• Echocardiographic evidence of thrombus in the left atrium, left atrial appendage, or other cardiac chamber, and in the inferior vena cava.
• Patients who within one month prior to implantation are known to have sepsis or any systemic infection that has not been successfully treated prior to device placement
• Active endocarditis or other infections producing bacteremia.
• Clinically relevant arrhythmia
• Patients whose vasculature, through which access to the defect is gained, is inadequate to accommodate the size of the device, the position controls or the introduction sheath
• Documented history of bleeding, clotting or coagulation disorders, untreated ulcer or any other contraindications to acetylsalicylic acid therapy, unless another anti-platelet agent can be administered for 6 months
• Known hypercoagulable state
• Anamnesis respectively diagnosis of pregnancy, or breastfeeding patients
• Any disorder in the investigator's opinion that could interfere with compliance or safety evaluation as well as any severe concurrent illness that would limit life expectancy (e.g. malignancies)
• Participation in an investigational drug or device trial within 30 days prior to selection (day 0) or current inclusion in any other clinical trial or research project
• Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this clinical trial or will not comply with requirements of the study
• Patients who are kept lawfully in an institution
• Clinical investigations shall be conducted in vulnerable populations only when they cannot be carried out in non-vulnerable populations and shall follow the additional ethics committee procedures where applicable. These clinical investigations shall be designed specifically to address health problems that occur in the vulnerable population, and offer the possibility of direct health-related benefit to the vulnerable population

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Carag AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Horst Sievert, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

CardioVaskuläres Centrum Frankfurt, Germany

Locations

CardioVaskuläres Centrum

Frankfurt, , Germany

Countries

Germany

Other Identifiers

2013.4678

Identifier Type: -

Identifier Source: org_study_id